ReviewNeurochemical research2026
Interleukin-17A as a Potential Mediator in Inflammatory Mechanisms of Insomnia.
Review in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Suicidality as a potential risk and therapeutic target during widespread GLP-1 receptor agonists use: implications of inflammation.Frontiers in synaptic neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The interaction between immune cytokines and sleep can be bidirectional, and the circadian rhythm balance has a crucial role to the immune and inflammatory regulation. Insomnia is a prevalent sleep disorder, in which occur modifications in immune expression, including the cytokines pattern. Some somnogenic cytokines, such as interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α) have been classically recognized for their direct association with sleep behavior and circadian alignment. More recent evidence has increasingly implicated the role of IL-17A in sleep disturbances and neuroinflammation. However, its specific relationship with insomnia disorder remains underexplored. This cytokine is considered as a relevant immune component in the pathways involved in inflammatory and autoimmune issues. Previous and rare studies on the behavior of IL-17A in insomnia related with comorbid disease suggested that increased IL-17A serum levels may be linked to poor sleep quality. We suggest that further experimental and clinical studies examining the role of IL-17A should shed more light in its relationship with insomnia; and on the immunological and neuroinflammatory associations with this sleep disorder.
Indexed as
Identifiers
42082723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.